$1.19 +0.01 (0.84%)
Rein Therapeutics, Inc. Common Stock (RNTX)
Rein Therapeutics, Inc. (RNTX) is a biopharmaceutical company focused on developing therapies targeting neurodegenerative diseases. The company's research emphasizes innovative approaches to treat conditions such as Parkinson’s disease and other neurodegenerative disorders, leveraging advances in molecular biology and drug delivery technologies.
Company News
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics received UK regulatory approval to launch a Phase 2 clinical trial for LTI-03, a potential breakthrough treatment for idiopathic pulmonary fibrosis (IPF), targeting fibrosis and lung tissue regeneration.